HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Neutral 52.0%

Neg 0% Neu 52% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $15 to $13.